A Phase 3, 12-week, Double-Blind, Placebo-Controlled

Project: Research project

Project Details

Description

A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/day as Treatment for Subjects with Moderate to Severe Parkinson's Disease
StatusFinished
Effective start/end date12/1/135/31/17

Funding

  • KYOWA KIRIN PHARMACEUTICAL DEVELOPMENT

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.